News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc.


7/2/2008 9:52:11 AM

TEL AVIV, Israel & CARLSBAD, Calif.--(BUSINESS WIRE)--PainReform and Encore Therapeutics today announced that the two companies have entered into a licensing and development agreement related to Encore Therapeutics’ ETI-211 product for the treatment of post surgical pain. The product, which is administered subdermally using Encore Therapeutics proprietary Phospholipid Gel technology, is currently in pre clinical testing.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES